MGX
Metagenomi, Inc. Common Stock
There isn't enough reported data to score MGX yet.
MGX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
MGX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
MGX PE Valuation
MGX has no meaningful PE right now: it lost money over the past year.
MGX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect MGX's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
MGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.49 | -$0.35 |
| Q2 2026 | -$2.48 | -$0.38 |
| Q1 2026 | -$2.29 | -$0.44 |
| Q4 2025 | -$2.36 | $0.00 |
| Q3 2025 | -$2.14 | +$0.36 |
| Q2 2025 | -$2.10 | +$0.42 |
| Q1 2025 | -$1.85 | +$0.73 |
| Q4 2024 | -$2.36 | -$0.43 |
MGX is still losing money, but less than at its worst: $2.49 per share over the past year, against $3.81 at its worst in late 2022.
MGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.2M | -75% |
| Q1 2026 | $1.2M | -70% |
| Q4 2025 | $3.9M | -59% |
| Q3 2025 | $8.7M | -25% |
| Q2 2025 | $8.5M | -57% |
| Q1 2025 | $4.1M | -63% |
| Q4 2024 | $9.6M | -22% |
| Q3 2024 | $11.5M | -6.9% |
MGX's revenue has slid since its 2024 peak: $2M last quarter, down 74% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1018% | -754 points |
| Q1 2026 | -1970% | -1296 points |
| Q4 2025 | -623% | -409 points |
| Q3 2025 | -264% | -69 points |
| Q2 2025 | -247% | -162 points |
| Q1 2025 | -674% | -414 points |
| Q4 2024 | -215% | -52 points |
| Q3 2024 | -194% | -13 points |
MGX's operating margin was −1018% last quarter, down 771 points from the same quarter a year ago, near the bottom of its range since 2022.
MGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.1M | +$2.3M |
| Q2 2026 | -$19.6M | +$1.7M |
| Q1 2026 | -$21.2M | +$1.9M |
| Q4 2025 | -$23.6M | +$3M |
| Q3 2025 | -$21.3M | +$6.5M |
| Q2 2025 | -$21.4M | +$5.6M |
| Q1 2025 | -$23.1M | +$7.6M |
| Q4 2024 | -$26.6M | -$4.3M |
MGX has burned cash in almost every quarter: −$84M over the past year, against −$92M the year before.
MGX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +117K shares |
| 1 year | +1.1% | +426K shares |
| 3 years | +0.8% | +303K shares |
MGX has 38M diluted shares, up 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
MGX Net Leverage
MGX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.9 | Oversold |
| Stochastic | 13.3 | Oversold |
MGX's weekly RSI is 22 (oversold) and its Stochastic is 13 (oversold).
MGX PE vs Healthcare Sector
MGX has no meaningful PE right now: it lost money over the past year.
MGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.87 | 18% below |
| 20 week MA | $1.07 | 34% below |
| 50 week MA | $1.32 | 46% below |
| 100 week MA | $1.73 | 59% below |
MGX is in a downtrend: it's below all four of its weekly moving averages, and 59% below its 100-week average.
MGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $10.3 | $3.74 | -64% |
| 2025 | $3.74 | $1.70 | -55% |
| 2026 YTD | $1.70 | $0.71 | -58% |
MGX has finished every year since 2024 lower, and it's down 58% so far in 2026.